Ocular Therapeutix Inc [OCUL] stock is trading at $8.13, up 6.97%. An important factor to consider is whether the stock is rising or falling in short-term value. The OCUL shares have gain 21.89% over the last week, with a monthly amount glided 61.95%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Ocular Therapeutix Inc [NASDAQ: OCUL] stock has seen the most recent analyst activity on June 20, 2024, when TD Cowen upgraded its rating to a Buy and also boosted its price target to $11 from $7. On February 09, 2024, BofA Securities initiated with a Buy rating and assigned a price target of $15 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $18 on April 21, 2023. H.C. Wainwright upgraded its rating to Buy for this stock on August 10, 2021, but kept the price target unchanged to $17. In a note dated December 28, 2020, H.C. Wainwright downgraded an Neutral rating on this stock.
Ocular Therapeutix Inc [OCUL] stock has fluctuated between $2.00 and $11.31 over the past year. Currently, Wall Street analysts expect the stock to reach $17.67 within the next 12 months. Ocular Therapeutix Inc [NASDAQ: OCUL] shares were valued at $8.13 at the most recent close of the market. An investor can expect a potential return of 117.34% based on the average OCUL price forecast.
Analyzing the OCUL fundamentals
Ocular Therapeutix Inc [NASDAQ:OCUL] reported sales of 59.84M for the trailing twelve months, which represents a growth of 10.47%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -1.53%, Pretax Profit Margin comes in at -1.93%, and Net Profit Margin reading is -1.93%. To continue investigating profitability, this company’s Return on Assets is posted at -0.21, Equity is -0.9 and Total Capital is -0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.76 points at the first support level, and at 7.39 for the second support level. However, for the 1st resistance point, the stock is sitting at 8.36, and for the 2nd resistance point, it is at 8.59.
Ratios To Look Out For
For context, Ocular Therapeutix Inc’s Current Ratio is 21.39. On the other hand, the Quick Ratio is 21.29, and the Cash Ratio is 19.88. Considering the valuation of this stock, the price to sales ratio is 21.04, the price to book ratio is 3.08.
Transactions by insiders
Recent insider trading involved Dugel Pravin,, that happened on May 23 ’24 when 21626.0 shares were sold. Chief Strategy Officer, Nayak Sanjay completed a deal on May 23 ’24 to sell 2274.0 shares. Meanwhile, 10% Owner SUMMER ROAD LLC bought 0.93 million shares on Feb 26 ’24.
